Valuation: Charles River Laboratories International, Inc.

Market Cap 15.71B 14.33B 13.19B 12.01B 22.53B 1,456B 23.75B 161B 63.8B 794B 58.95B 57.71B 2,491B P/E 2026 *
37.3x
P/E 2027 * 34.9x
Enterprise Value 17.74B 16.18B 14.9B 13.56B 25.44B 1,644B 26.82B 181B 72.05B 896B 66.57B 65.17B 2,813B EV / Sales 2026 *
4.49x
EV / Sales 2027 * 4.25x
Free-Float
95.88%
Yield 2026 *
-
Yield 2027 * -
11-20 Baird Adjusts Price Target on Charles River Laboratories to $365 From $364 MT
11-12 Charles River Laboratories International, Inc. Expands Global Microbial Solutions Network Through Investments in Manufacturing, Customer Support, and Sustainability CI
11-12 TD Cowen Adjusts Price Target on Charles River Laboratories International to $388 From $325 MT
11-11 TD Cowen Adjusts Charles River Laboratories Price Target to $388 From $325, Maintains Buy Rating MT
11-11 Analyst recommendations: Apple, Diamondback Energy, Vertiv Holdings, Coreweave… Zonebourse
11-10 Frontage Agrees to Take-Private Offer MT
11-09 HK-listed Frontage to be taken private in $616 million deal backed by Charles River RE
11-09 Charles River to Acquire Frontage Bioanalysis, DMPK Businesses for $470 Million MT
11-09 Deals of the day-Mergers and acquisitions RE
11-09 Charles River Laboratories International, Inc., Hongkong Tigermed Consulting Co., ltd. and Song Li, Chairman of the Board of Frontage Holdings Corporation agreed to acquire remaining 26.65% stake in Frontage Holdings Corporation. CI
11-09 Charles River Laboratories International, Inc. (NYSE : CRL) entered into definitive agreements to acquire Bioanalysis and DMPK operations in Exton, Pennsylvania of Frontage Holdings Corporation (SEHK : 1521) for $545 million. CI
11-05 UBS Adjusts Price Target on Charles River Laboratories International to $387 From $357, Maintains Buy Rating MT
11-05 Rothschild & Co Redburn Adjusts Price Target on Charles River Laboratories International to $375 From $318 MT

Last Transcript: Charles River Laboratories International, Inc.

1 day-4.15%
1 week-7.77%
Current month-12.55%
1 month+4.77%
3 months+8.39%
6 months+106.21%
Current year+57.57%
1 week 310.52
Extreme 310.52
343.57
1 month 310.52
Extreme 310.52
379.63
Current year 146.2
Extreme 146.195
379.63
1 year 146.2
Extreme 146.195
379.63
3 years 91.86
Extreme 91.8609
379.63
5 years 91.86
Extreme 91.8609
385.1
10 years 69.51
Extreme 69.51
460.21
Manager TitleAgeSince
Chief Executive Officer 56 05/05/2026
Director of Finance/CFO 58 06/04/2026
Chief Tech/Sci/R&D Officer 45 12/01/2026
Director TitleAgeSince
Chairman 75 01/01/2000
Director/Board Member 56 05/05/2026
Chairman 69 05/05/2026
Date Insider Type Main position Quantity % Market Cap. Importance
10/22/26 A Exercice

Director

72,126 0.1511%
10/21/26 A Exercice

Executive/Senior Manager

6,468 0.0135%
10/5/26 A Exercice

Executive/Senior Manager

2,943 0.0062%
Change 5-day change 1-year change 3-year change Capi.($)
-4.15%-7.77%+94.46%+66.27% 15.71B
-2.49%-6.35%+51.07%+64.95% 65.42B
-0.63%-3.81%+6.95%+88.55% 58.91B
-2.37%-2.22%+22.96%+83.44% 55.24B
-2.19%-6.02%+10.50%+109.19% 45.66B
-1.89%-9.33%+13.03%+20.04% 41.29B
-0.93%+1.67%+20.83%+45.03% 36.82B
+1.11%-8.59%+128.56%+655.74% 34.48B
-0.80%-1.73%+75.29%+56.47% 32.5B
-2.17%+19.70%-30.57%+469.42% 31.69B
Average -1.65%-0.87%+39.31%+165.91% 42B
Weighted average by Cap. -1.59%-1.33%+33.99%+148.21%

Financials

2026 *2027 *
Net sales 3.95B 3.6B 3.32B 3.02B 5.67B 366B 5.97B 40.41B 16.05B 200B 14.83B 14.52B 627B 4.06B 3.7B 3.41B 3.1B 5.82B 376B 6.14B 41.5B 16.48B 205B 15.23B 14.91B 643B
Net income 423M 386M 355M 323M 607M 39.21B 640M 4.33B 1.72B 21.37B 1.59B 1.55B 67.07B 431M 393M 362M 329M 618M 39.92B 651M 4.4B 1.75B 21.76B 1.62B 1.58B 68.28B
Net Debt 2.03B 1.85B 1.71B 1.55B 2.91B 188B 3.07B 20.76B 8.25B 103B 7.62B 7.46B 322B 1.55B 1.41B 1.3B 1.18B 2.22B 143B 2.34B 15.82B 6.28B 78.15B 5.8B 5.68B 245B
Projected Income Statement - Annual - Charles River Laboratories International, Inc.
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).
Employees
19,000
Date Price Change Volume
20/11/26 $314.32 -4.15% 1,151,474
19/11/26 $327.93 -1.60% 495,099
18/11/26 $333.25 +0.33% 516,509
17/11/26 $332.16 -1.00% 697,548
16/11/26 $335.52 -0.72% 693,841
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Charles River Laboratories International, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
327.93USD
Average target price
350.64USD
Spread / Average Target
+6.93%